BMY News 50.95 04/24/2014 05:01:42 Bristol-Myers Squibb Company

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bristol-Myers Squibb Company (BMY) 50.95 $BMY

Will These 3 Dividend Stocks Impress Investors This Earnings Season?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Earnings season already has produced its fair share of surprises, but big pharma's hardly even broken out of the gate so far. However, a trio of major drugmakers are set to release their quarterly results in the next two weeks, and all eyes in the...

Final Glance: Pharmaceuticals companies
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Bristol-Myers, Samsung BioLogics Extend Ties - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:30PM CDT
Bristol-Myers Squibb Company (BMY) expanded its existing manufacturing agreement with Samsung BioLogics.

AbbVie Files for HCV Combination Therapy in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:21PM CDT
AbbVie submitted a NDA to the FDA for its investigational hepatitis C virus infection therapy.

Midday Glance: Pharmaceuticals companies
AP - Wed Apr 23, 12:37PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Early Glance: Pharmaceuticals companies
AP - Wed Apr 23, 9:29AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

Say Hello to the New Fastest Growing Drug in History!
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 23, 9:03AM CDT
Take every guess you had as to how well Gilead Sciences would perform in the first-quarter, no matter how outrageous, and completely throw them out the window because Gilead would have trumped it! Break out your thesaurus because you'll need...

Global T-Cell Leukemia Therapeutics Pipeline Review 2014 - Analysis of 10 Companies & 14 Drug Profiles
M2 - Wed Apr 23, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/943p82/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Mundipharma International Limited - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - CytImmune Sciences, Inc. - Applied Immune Technologies Ltd Drug Profiles - mogamulizumab - forodesine hydrochloride - lenalidomide - Anti-Tac(Fv)-PE38 Immunotoxin - PF-03084014 - BMS-906024 - PCI-34051 - SL-101 - Lenaldekar - CYT-91000 - NK-314 - Immunotoxins - TCRL Antibodies For HTLV-1 - L1AD3 For more information visit http://www.researchandmarkets.com/research/94...l_leukemia

Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma
Marketwire - Wed Apr 23, 6:30AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced the opening of an investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's ipilimumab (Yervoy(R)), for the treatment of advanced melanoma. Bavituximab is an upstream immune checkpoint inhibitor that targets phosphatidylserine (PS), a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells. Preclinical data in a model of melanoma demonstrate that the combination of a bavituximab equivalent and ipilimumab yield enhanced anti-tumor activity compared to ipilimumab alone. The trial is being conducted at the University of Texas Southwestern Medical Center, Dallas, and led by Arthur E. Frankel, M.D., Associate Professor of Internal Medicine at the Simmons Comprehensive Cancer Center. Bavituximab, Peregrine's lead immuno-oncology candidate, is being evaluated in second-line non-small cell lung cancer (NSCLC), as part of the SUNRISE pivotal Phase III clinical trial.

Celgene to Rise Like a Phoenix: Opinion
at The Street - Wed Apr 23, 5:21AM CDT
Celgene's share price offers both growth or value investors something to like.

Bristol-Myers Squibb expands manufacturing agreement with Samsung BioLogics
M2 - Wed Apr 23, 4:13AM CDT
Biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) declared on Tuesday that it has extended its existing manufacturing agreement with Samsung BioLogics for an undisclosed value.

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement
Business Wire - Tue Apr 22, 6:00PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics today announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the agreement are not disclosed.

Global Synthetic Biology Market 2013-2019 - Genome Engineering, DNA Sequencing, Bioinformatics & Biological Components and Integrated Systems
M2 - Tue Apr 22, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/29nxfg/synthetic_biology) has announced the addition of the "Synthetic Biology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2013 - 2019" report to their offering. Synthetic biology is a synergistic combination of biology and engineering for the construction of artificial biological system in order to gain desired functions (i.e. to reduce cost or improve efficacy). It comprises nascent technologies that enable synthesis of novel biological parts and organisms that are used in the field of healthcare, chemicals, agriculture and others (biosecurity, R&D and energy and environment). The synthetic biology market is witnessing rapid growth owing to increase in demand for renewable fuels and bio-based chemicals and inexpensive drugs and vaccines that utilizes synthetic biology technologies and products. In addition, participation of various organizations such as BioBricks, DIYbio and SynBERC, for the development of synthetic biology field will further augment the growth of this market during the forecast period. However, high cost and strict regulations to use synthetic biology techniques hampers the growth of this market. Synthetic biology market is segmented mainly by products, by technologies and by applications. Synthetic biology, by product segment is classified as core products and enabling products. Core products are further segmented into synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. The synthetic biology market by core products was dominated by synthetic DNA market in 2012 owing to the commercial availability of this product, compared to other synthetic core products expected to be launched in the market in coming years. Synthetic biology market by technologies is segmented as genome engineering, DNA sequencing, bioinformatics and biological components and integrated systems. Genome engineering technology can be used to modify genetic foods, gene cloning and gene therapy. Thus, application of genome engineering increases the scope to utilize this technique and hence accentuates the growth of this market. Applications of synthetic biology are healthcare, chemicals, agriculture and others. Synthetic biology in healthcare holds largest market share in terms of revenue due to high utilization of synthetic biology techniques to produce cheap drugs and vaccines. Also, commercial availability of synthetic DNA and synthetic genes supports the growth of the healthcare application in the synthetic biology market. Agriculture segment is expected to grow at the highest growth rate during the forecast period. The global synthetic biology market is segmented into the following categories: Products - Core Products - - Synthetic DNA - - Synthetic Genes - - Synthetic Cells - - XNA (Xeno Nucleic Acid) - - Chasis Organisms - Enabling Products - - DNA Synthesis - - Oligonucleotide Synthesis Technologies - Genome Engineering - DNA Sequencing - Bioinformatics - Biological Components and Integrated Systems Applications - Healthcare - Chemicals (Including Bio-Fuels) - Agriculture - Others (Biosecurity, R&D, Energy and Environment) Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Synthetic Biology Market, by Products - Global Synthetic Biology Market, by Technologies - Global Synthetic Biology Market, by Applications - Global Synthetic Biology Market, by Geography - Competitive Landscape - Recommendations - Company Profiles - Agrivida, Inc. - Amyris, Inc. - Algenol Biofuels, Inc. - ATG:biosynthetics GmbH - Bayer AG - Bristol-Myers Squibb - BIONEER CORPORATION - Biosearch Technologies, Inc. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - DuPont, Inc. - Evolva SA - Exxon Mobil Corporation - Ginkgo Bioworks - GeneWorks Pty Ltd. - Genomatica, Inc. - GeneScript Corporation - Gevo, Inc. - Green Biologics Limited - New England Biolabs, Inc. - OriGene Technologies, Inc. - REG Life Sciences, LLC - Royal DSM - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/29...ic_biology

Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D. Pfizer is apparently not afraid...

SmarTrend Watching for Potential Pullback in Shares of Bristol-Myers Squibb After 2.12% Gain
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Look for Shares of Bristol-Myers Squibb to Potentially Pullback after Yesterday's 2.12% Rise
Comtex SmarTrend(R) - Mon Apr 21, 4:13PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $49.58 to a high of $50.60. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $49.68 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Galectin Therapeutics Rises on GR-MD-02 Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 3:45PM CDT
Share price of Galectin Therapeutics jumped 12.9% after the company announced dosing of the first patient in cohort 2 of a phase I study on GR-MD-02.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 39

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
Hyundai’s Third SUV Crown Matters Beyond the Trophy

Updated Category News Views 66

A Three-Year Streak Is Not Just Decorative Three straight SUV-brand wins can make even a cynical car watcher pause. Hyundai has been named U.S. News & World Report’s 2027 Best SUV Brand after editors assessed vehicles from 39 brands, and that is a useful bit of outside validation in a segment where nearly everybody is throwing sheet metal, screens, and marketing dollars...

Continue Reading
Hisense Puts Heat-Pump Smarts Into Laundry Loads

Updated Category News Views 43

Laundry is where flashy appliance promises usually go to die, buried beneath damp towels and a sweater somebody was afraid to ruin. Hisense is taking a sensible swing at that mess with its 5i heat-pump washer dryer: a standard-size machine that claims a bigger drum, 12kg washing capacity, 8kg drying capacity, lower-temperature drying and more automated decisions. That is...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 38

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 58

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
YPF’s 2027 Reserves Platform Move Deserves Attention

Updated Category News Views 51

Reservoir software rarely makes anyone pound the table, but this one deserves a hard look. YPF, Argentina’s largest oil and gas company, says it will begin deploying Ikon Science’s MOSAIC reserves planning and management platform in 2027. That is not a new well, a pipeline expansion, or a barrel-count upgrade. It is the machinery behind the machinery: the systems used...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 73

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 62

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 31

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
Discount Tire’s $10 Correction Matters This Black Friday

Updated Category News Views 115

A ten-dollar correction is not a catastrophe, but it is precisely the sort of loose screw that deserves a glance before Black Friday shouting gets underway. Discount Tire says an earlier version of its Nov. 17, 2026 promotion release listed combined instant savings of $390 when the correct maximum is $380. The company issued the correction and supplied a revised release....

Continue Reading

Top 5 Most Recently Viewed Articles

WM Technology Faces Class Action Lawsuit: What Investors Need to Know

Updated Category News Views 69

Understanding WM Technology's Legal Challenges WM Technology, Inc. has recently found itself at the center of a class action lawsuit, raising significant concerns among its investors. This legal action has been initiated by a prominent law firm advocating for shareholder rights, highlighting serious allegations against the company. Investors are encouraged to stay...

Continue Reading
Nimbello's SyteLine Customer Growth Signals Bright Future Ahead

Updated Category News Views 224

Nimbello's Impressive Growth in the SyteLine Market Nimbello, renowned for its innovative Accounts Payable (AP) automation solutions, has achieved a significant milestone by doubling its customer base among SyteLine users throughout the year. This exciting growth showcases Nimbello's capability and positions it as a leader within the SyteLine ecosystem. Understanding...

Continue Reading
FRE Nicotine Pouches and PBR: A Thrilling Partnership Ahead

Updated Category News Views 169

FRE Nicotine Pouches and PBR: A Thrilling Partnership Ahead In an exciting development for sports enthusiasts, FRE® Nicotine Pouches has joined forces with Professional Bull Riders (PBR) as their official partner for the iconic Unleash The Beast event series. This remarkable multi-year sponsorship marks a significant milestone for FRE, making it their biggest sports...

Continue Reading
ADP Strengthens Workforce Management with WorkForce Software

Updated Category News Views 92

ADP Expands Its Workforce Management Solutions ADP (NASDAQ: ADP), a leading global technology company in human capital management (HCM) solutions, has made a significant move by acquiring WorkForce Software. This strategic acquisition aims to enhance ADP's workforce management offerings and bolster innovation to address the evolving needs of businesses worldwide....

Continue Reading
MiniLuxe Secures Funding through Innovative Private Placement

Updated Category News Views 305

MiniLuxe Announces a Strategic Private Placement MiniLuxe Holding Corp. has recently made headlines by initiating a non-brokered private placement aimed at raising up to $5 million. This move is geared toward furthering the company’s growth trajectory and expanding its footprint in the beauty and self-care industry. Offering Details and Investor Opportunities This...

Continue Reading